89Bio (ETNB) FY 2025 Conference June 11, 2025 11:20 AM ET Speaker0 Great. Good morning, everyone. Thanks so much for joining us. I'm really pleased to be joined by Rohan Palikar, CEO of eighty nine Bio. Thank you so much. Speaker1 Andrea, great to be here. Thanks for having us. Speaker0 Yeah. Maybe to start, let's just talk about the NASH space, the evolution. There have been so many developments, both on the clinical side as well as the approved drug last year. How do you see the NASH space evolving from h ...

Akero Therapeutics (AKRO) FY 2025 Conference June 10, 2025 02:40 PM ET Speaker0 Thanks everyone for joining us. I'm Andrew Newkirk, one of the biotech analysts here at Goldman Sachs. I'm really pleased to be joined by Andrew Chang, President and CEO of Akerro. Thanks so much, Andrew. Speaker1 Thanks for having me. Speaker0 Maybe at a high level, let's start with where the NASH field is now. We've obviously seen a lot of development both on the clinical development side with the commercially approved drug la ...

SAN FRANCISCO, June 04, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11, 2025 at 11:20 AM EDT and participate in one-on-one investor meetings ...

医药 本周医药板块上涨 1.27%，百济 BTK PROTAC 启动头对头 3 期临 床 证券研究报告 | 行业周报 2025 年 05 月 19 日 | 股票 | 股票 | 投资 | EPS （元） | | PE | | | --- | --- | --- | --- | --- | --- | --- | | 代码 | 名称 | 评级 | 2025E | 2026E | 2025E | 2026E | | 002755.SZ | 奥赛康 | 买入 | 0.2 | 0.28 | 87.7 | 62.64 | | 01952.HK | 云顶新耀 | 买入 | -0.94 | 0.58 | - | - | | 600079.SH | 人福医药 | 增持 | 1.59 | 1.86 | 12.83 | 10.97 | | 688192.SH | 迪哲医药 | 增持 | -1.33 | -0.08 | - | - | | 688315.SH | 诺禾致源 | 买入 | 0.53 | 0.62 | 26.51 | 22.66 | | 688321.SH | 微芯生物 | 增持 | 0.05 | 0.23 | 349. ...

89Bio (ETNB) 2025 Conference May 14, 2025 01:40 PM ET Speaker0 This joining us on this, our second day of Bank of America's twenty twenty five health care conference here in Las Vegas. My name is Jason Zemanski. I'm one of SMID cap analysts here at the bank, And I'm so pleased to have join me on stage, Rohan Palakkar. Thank you so much for joining us. Speaker1 Great to be here, Jason. Thanks for having us. Well, Speaker0 maybe let's start broadly, especially for those newer to the story. What about FGF21 ma ...

Akero Therapeutics (AKRO) 2025 Conference May 13, 2025 04:40 PM ET Speaker0 And I'm very pleased to have joined me in our first slot of the afternoon session, Andrew Chang, CEO of Vaccaro. Thank you so much for joining us. Speaker1 Thank you for having us, Jason. Well, perfect. Speaker0 Maybe just to start broadly to provide a little context for those newer to the story, Can you describe the role of FGF21 in the pathogenesis of liver fibrosis? Kind of acknowledging that it is somewhat early, but what are so ...

SAN FRANCISCO, May 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company's Management will participate in the following investor conferences during the month of May: Annie Chang 89bio, Inc. investors@89bio.com PJ Kelleher LifeSci Advisors, LLC 617-430-7579 pkelleher@lifesciad ...